Publikationen in Zusammenarbeit mit Forschern von Medical College of Wisconsin (24)

2024

  1. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients

    Dermatology and Therapy, Vol. 14, Núm. 3, pp. 593-612

2023

  1. Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)

    Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 659-666

  2. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

    New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347

  3. Corrigendum to GoldVariants, a resource for sharing rare genetic variants detected in bleeding, thrombotic, and platelet disorders: Communication from the ISTH SSC Subcommittee on Genomics in Thrombosis and Hemostasis [J Thromb Haemost. 2021 Oct;19(10):2612-2617] (Journal of Thrombosis and Haemostasis (2021) 19(10) (2612–2617), (S1538783622021559), (10.1111/jth.15459))

    Journal of Thrombosis and Haemostasis

2022

  1. Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors

    American Journal of Hematology, Vol. 97, Núm. 7, pp. 877-884

  2. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies

    The Lancet. Haematology, Vol. 9, Núm. 5, pp. e374-e384

2021

  1. GoldVariants, a resource for sharing rare genetic variants detected in bleeding, thrombotic, and platelet disorders: Communication from the ISTH SSC Subcommittee on Genomics in Thrombosis and Hemostasis

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 10, pp. 2612-2617

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  3. International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

    Leukemia, Vol. 35, Núm. 1, pp. 18-30

  4. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

    The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118

2020

  1. A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma

    American Journal of Hematology, Vol. 95, Núm. 5, pp. 503-509

  2. Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients

    Leukemia and Lymphoma, Vol. 61, Núm. 8, pp. 1885-1893

2018

  1. Association between response kinetics and outcomes in relapsed/refractory multiple myeloma: analysis from TOURMALINE-MM1

    Leukemia, Vol. 32, Núm. 9, pp. 2032-2036

  2. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies

    The Lancet Haematology, Vol. 5, Núm. 11, pp. e563-e598

2017

  1. Impact of prior therapy on the efficacy and safety of oral ixazomiblenalidomide-dexamethasone vs. Placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

    Haematologica, Vol. 102, Núm. 10, pp. 1767-1775

  2. Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

    British Journal of Haematology, Vol. 178, Núm. 4, pp. 571-582

  3. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: A multicenter IMWG study

    Leukemia, Vol. 31, Núm. 11, pp. 2443-2448

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

  3. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment

    Journal of Clinical Oncology, Vol. 34, Núm. 13, pp. 1544-1557